JPWO2020219960A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020219960A5
JPWO2020219960A5 JP2021562992A JP2021562992A JPWO2020219960A5 JP WO2020219960 A5 JPWO2020219960 A5 JP WO2020219960A5 JP 2021562992 A JP2021562992 A JP 2021562992A JP 2021562992 A JP2021562992 A JP 2021562992A JP WO2020219960 A5 JPWO2020219960 A5 JP WO2020219960A5
Authority
JP
Japan
Prior art keywords
concentration
subject
antibody
serum
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545312A (ja
JP2022545312A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029930 external-priority patent/WO2020219960A1/en
Publication of JP2022545312A publication Critical patent/JP2022545312A/ja
Publication of JPWO2020219960A5 publication Critical patent/JPWO2020219960A5/ja
Publication of JP2022545312A5 publication Critical patent/JP2022545312A5/ja
Pending legal-status Critical Current

Links

JP2021562992A 2019-04-24 2020-04-24 関節リウマチの診断及び処置の方法 Pending JP2022545312A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962837793P 2019-04-24 2019-04-24
US62/837,793 2019-04-24
EP20305193 2020-02-27
EP20305193.3 2020-02-27
PCT/US2020/029930 WO2020219960A1 (en) 2019-04-24 2020-04-24 Methods of diagnosis and treatment of rheumatoid arthritis

Publications (3)

Publication Number Publication Date
JP2022545312A JP2022545312A (ja) 2022-10-27
JPWO2020219960A5 true JPWO2020219960A5 (https=) 2023-04-27
JP2022545312A5 JP2022545312A5 (https=) 2023-04-27

Family

ID=70736802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562992A Pending JP2022545312A (ja) 2019-04-24 2020-04-24 関節リウマチの診断及び処置の方法

Country Status (15)

Country Link
US (2) US12440561B2 (https=)
EP (1) EP3959240A1 (https=)
JP (1) JP2022545312A (https=)
KR (1) KR20220088829A (https=)
CN (1) CN114651010A (https=)
AU (1) AU2020261431A1 (https=)
BR (1) BR112021021077A2 (https=)
CA (1) CA3137909A1 (https=)
CO (1) CO2021015660A2 (https=)
IL (1) IL287263A (https=)
MA (1) MA55760A (https=)
MX (1) MX2021012969A (https=)
SG (1) SG11202111742QA (https=)
TW (1) TW202106712A (https=)
WO (1) WO2020219960A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
CN117138126B (zh) * 2023-08-30 2024-04-09 江苏恰瑞生物科技有限公司 定向清除炎症因子il-6的过滤材料及过滤柱
KR102818005B1 (ko) 2025-03-04 2025-06-11 김환배 전자렌지용 저당밥솥

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5432103A (en) 1977-08-16 1979-03-09 Nissan Motor Co Ltd Preparing apparatus for composite molten metal containing solid particles in dispersed state
JPS5870649A (ja) 1981-10-22 1983-04-27 Toyota Motor Corp ダイバ−シテイ受信システム
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
JP2998976B2 (ja) 1989-07-20 2000-01-17 忠三 岸本 ヒトインタ―ロイキン―6レセプターに対する抗体
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
EP1097945B1 (en) 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il-6产生所致疾病的药物组合物
EP0800829B2 (en) 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
ES2264135T3 (es) 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
DK0923941T3 (da) 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
AU747883B2 (en) 1997-08-15 2002-05-30 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DK1074268T3 (da) 1998-03-17 2008-04-28 Chugai Pharmaceutical Co Ltd IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
ATE350060T1 (de) 1998-08-24 2007-01-15 Chugai Pharmaceutical Co Ltd Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6670373B1 (en) 1999-10-07 2003-12-30 Eli Lilly And Company Compounds and method for inhibiting MRP1
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
DE60133029T2 (de) 2000-10-25 2009-03-12 Chugai Seiyaku K.K. Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
AU2003211990A1 (en) 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1673396A1 (en) 2003-09-22 2006-06-28 BioVation GmbH & Co.KG. Use of antibodies for reducing the biological effectiveness of il-6
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
BRPI0506679A (pt) 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
WO2006046661A1 (ja) 2004-10-28 2006-05-04 Osaka University インターロイキン-6阻害剤
EP1828250A2 (en) 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CN101312744A (zh) 2005-11-22 2008-11-26 惠氏公司 免疫球蛋白融合蛋白制剂
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
US20070143168A1 (en) 2005-12-19 2007-06-21 Lucent Technologies Inc. Meeting scheduling service
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
BRPI0713421A2 (pt) 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en) 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP4885308B2 (ja) 2009-03-19 2012-02-29 中外製薬株式会社 改良された抗体分子を含有する製剤
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JP5607736B2 (ja) 2009-07-07 2014-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎ウイルスプロテアーゼ阻害剤のための医薬組成物
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠL-1β 관련 병태의 치료 방법
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9261526B2 (en) 2010-08-26 2016-02-16 Blast Motion Inc. Fitting system for sporting equipment
TWI603738B (zh) 2010-11-08 2017-11-01 建南德克公司 皮下投予抗-il-6受體抗體
US8440890B1 (en) 2011-03-09 2013-05-14 Pioneer Hi Bred International Inc Maize variety inbred PH1D0D
CA2746171C (en) 2011-07-13 2018-11-06 William Jani Retrievable stimulation frac (rsf) plug
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
CN103947096B (zh) 2011-10-21 2016-09-21 Abb研究有限公司 用于检测ac/dc转换器中失效整流器的方法和系统
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
SG11201601625UA (en) 2013-09-11 2016-04-28 Glenn Abrahmsohn Hypertonic antimicrobial therapeutic compositions
JP6343011B2 (ja) 2013-10-07 2018-06-13 プレステージ バイオファーマ プライベート リミテッド 抗体発現用バイシストロニック発現ベクター及びそれを用いた抗体の生産方法
ES2799439T3 (es) 2013-11-22 2020-12-17 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas
AU2014352801B2 (en) * 2013-11-22 2020-05-28 Regeneron Pharmaceuticals, Inc. Compositions for the treatment of rheumatoid arthritis and methods of using same
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
AU2015317905A1 (en) * 2014-09-16 2017-03-16 Regeneron Pharmaceuticals, Inc. Compositions for improving the health related quality of life of rheumatoid arthritis patients
TW201723174A (zh) 2015-09-03 2017-07-01 持田製藥股份有限公司 重組蛋白質的製造方法
IL319993A (en) 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
WO2017106312A1 (en) 2015-12-18 2017-06-22 Drexel University Methods of modulating levels of il-6 and pd-l1
BR112018067851A2 (pt) 2016-03-07 2019-02-05 Regeneron Pharma composições e métodos para o tratamento de artrite reumatoide
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
WO2018007442A1 (en) * 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
AU2019329958B2 (en) 2018-08-29 2025-05-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
CH715771A2 (de) 2019-01-23 2020-07-31 Pedretti Mauro Verfahren und Vorrichtung zum Speichern von Energie.
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
BR112021025060A2 (pt) 2019-06-12 2022-02-22 Regeneron Pharma Dosagem modificada de tocilizumab subcutâneo para artrite reumatóide
US12135885B2 (en) 2020-01-31 2024-11-05 Hewlett Packard Enterprise Development Lp Virtual storage policies for virtual persistent volumes
IL298088A (en) 2020-05-26 2023-01-01 Sanofi Biotechnology The compositions containing an antibody against the interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using them
JP7841752B2 (ja) 2020-05-29 2026-04-07 サノフィ・バイオテクノロジー 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法

Similar Documents

Publication Publication Date Title
Baenziger et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology
Molina et al. Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells
Saltini et al. T lymphocytes compartmentalized on the epithelial surface of the lower respiratory tract express the very late activation antigen complex VLA-1
US8784812B2 (en) Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
WO2002096461A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
Davies et al. Clinical experience of IL-6 blockade in rheumatic diseases—implications on IL-6 biology and disease pathogenesis
TWI859192B (zh) 包含抗il-6受體抗體之bbb功能低下之抑制劑
JP2018135370A (ja) 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
JPH07503851A (ja) 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法
JP2018138551A (ja) 関節リウマチの治療
WO2021128027A1 (zh) TACI-Fc融合蛋白及其用途
Kiani et al. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients
JP2022542035A (ja) 抗pre-s1 hbv抗体を用いるhbv感染症の治療方法
McInnis et al. Synthesis of α-chemokines IP-10, I-TAC, and MIG are differentially regulated in human corneal keratocytes
CZ20013270A3 (cs) Protilátkové a chemokinové konstrukty a jejich pouľití při léčbě autoimunitních chorob
US12427184B2 (en) Treatment of immunosuppressed subjects
JPWO2020219960A5 (https=)
RU2306934C1 (ru) Способ лечения больных хроническим вирусным гепатитом c
Aukrust et al. Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-α activity in human immunodeficiency virus type 1 infection
US20260028397A1 (en) Methods of treating ankylosing spondylitis
Seino et al. Inhibition of autoimmune diabetes in NOD mice with serum from streptococcal preparation (OK‐432)‐injected mice
RU2021134061A (ru) Способы диагностики и лечения ревматоидного артрита
Shinde et al. Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production
Stegeman et al. PREVENTION OF RELAPSES OF WEGENER'S GRANULOMATOSIS BY TREATMENT WITH TRIMETHOPRIM-SULFAMETHOXAZOLE. A MULTI-CENTER PLACEBO CONTROLLED TRIAL IN 81 PATIENTS
Kristensson et al. A new approach for the pathogenesis of human African trypanosomiasis